Trinity Biotech

Trinity Biotech Book Value per Share

The Book Value per Share of Trinity Biotech (TRIB) as of Nov 20, 2026 is -0.20 USD. In the previous year, Book Value per Share was -0.10 USD — a change of 104.60% (lower).

Book Value per Share

-0.20USD

YoY

104.60%

Last updated:

Book Value per Share of Trinity Biotech is 2025 -0.20 USD. Book Value per Share of Trinity Biotech was 2024 -0.10 USD. It decreases by 104.60% lower compared to the previous year.

The Trinity Biotech Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.12 USD
Jan 1, 2019
0.01 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.07 USD
Jan 1, 2024
-0.10 USD
Jan 1, 2025
-0.20 USD
The Trinity Biotech Book Value per Share history
YEARBook Value per ShareYoY
-0.20USD+104.60%
-0.10USD+46.90%
-0.07USD+1,000.60%
-0.01USD+582.13%
-0.00USD-85.62%
-0.01USD-147.08%
0.01USD-89.30%
0.12USD-32.43%
0.18USD-40.04%
0.31USD-49.17%
0.61USD+8.59%
0.56USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Book Value per Share of Trinity Biotech is -0.20 USD in 2025.

Book Value per Share of Trinity Biotech changed from -0.10 USD to -0.20 USD, representing a 104.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech